Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00582894 · ClinicalTrials.gov registry record · NA
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
A NA study, sponsored by University of Oklahoma.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT00582894 is a NA study that has completed, run by University of Oklahoma. The registered enrollment target is 17 participants.
The verdict
NCT00582894, a NA study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases
Interventions
- DRUG Busulfex, Fludarabine, ALemtuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2005-02 |
| Est. Completion | 2008-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00582894
The ClinicalTrials.gov registry entry for NCT00582894 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Busulfex, Fludarabine, ALemtuzumab is the first listed.
NCT00582894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00582894 about?
NCT00582894 is a clinical study titled "Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases". To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases
What is the current status of trial NCT00582894?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2005-02. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00582894?
The interventions under investigation include: Busulfex, Fludarabine, ALemtuzumab (DRUG).
Who is sponsoring clinical trial NCT00582894?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.